Superoxide dismutase mimetics

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Dienstag, November 14, 2023
NDA, Cisplatin, Disclosure, Galera, Chronic kidney disease, Annual general meeting, Superoxide dismutase, ASN, ASTRO, Food, Type, SBRT, Head, Incidence, Investment, New Drug Application, Clinical trial, American Society of Nephrology, Insurance, Patient, Workforce, Research, Radiation therapy, Death, FDA, CKD, Neoplasm, LAPC, Therapy, Manganese, Enterocyte, GRECO, Cancer, CRL, Symantec Endpoint Protection, Combination, Superoxide dismutase mimetics, Layoff, Society, HNC, Poster, Pharmaceutical industry

MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2023 and provided recent corporate updates.

Key Points: 
  • The Company is exploring potential strategic alternatives, as it is not feasible to conduct an additional trial with the Company’s current resources.
  • Research and development expenses were $6.1 million in the third quarter of 2023, compared to $8.1 million for the same period in 2022.
  • General and administrative expenses were $5.0 million in the third quarter of 2023, compared to $4.9 million for the same period in 2022.
  • As of September 30, 2023, Galera had cash, cash equivalents and short-term investments of $28.4 million.

Science Translational Medicine Article Shows Galera’s Selective Dismutase Mimetic Synergizes with Radiotherapy to Ablate Tumors

Retrieved on: 
Mittwoch, Mai 12, 2021
Physical sciences, Antioxidants, Radiobiology, Oxidoreductases, Enzymes, Superoxide dismutase mimetics, Chemistry, Natural sciences, Radiation therapy, Dismutase, Mucositis, Radiation

The synergy between the mimetic and radiotherapy increased with larger daily doses (\xe2\x80\x9cfractions\xe2\x80\x9d) of radiation.

Key Points: 
  • The synergy between the mimetic and radiotherapy increased with larger daily doses (\xe2\x80\x9cfractions\xe2\x80\x9d) of radiation.
  • Moreover, in the range of fraction sizes typical of SBRT, the combination ablated many of the tumors.
  • In addition, as previously published, the authors report that by removing the superoxide, the dismutase mimetics protected normal cells from radiation toxicity.
  • Galera\xe2\x80\x99s lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a selective small molecule dismutase mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM).

Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference

Retrieved on: 
Mittwoch, Mai 5, 2021
Antioxidants, Mucositis, Radiation therapy, Superoxide dismutase mimetics, Physical sciences, Galera, Natural sciences, Physics

Galera\xe2\x80\x99s lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a selective small molecule dismutase mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM).

Key Points: 
  • Galera\xe2\x80\x99s lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a selective small molecule dismutase mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM).
  • The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy.
  • Galera also intends to initiate the GRECO-2 Phase 2b trial of GC4711 in combination with SBRT in patients with LAPC.
  • Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com .\n'

Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBRT for Locally Advanced Pancreatic Cancer

Retrieved on: 
Dienstag, September 8, 2020
Enzymes, Chemical substances, Chemistry, Antioxidants, Oxidoreductases, Reactive oxygen species, Metalloproteins, Superoxide dismutase mimetics, Superoxide dismutase, Superoxide, Radiation therapy, Hydrogen peroxide

GC4419 is an investigational, highly selective small molecule superoxide dismutase mimetic designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen.

Key Points: 
  • GC4419 is an investigational, highly selective small molecule superoxide dismutase mimetic designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen.
  • Details of the presentation are as follows:
    Abstract Title: Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC)
    For more information about the 2020 ASTRO Annual Meeting, please visit https://www.astro.org/Meetings-and-Education/Micro-Sites/2020/Annual-Mee... .
  • Avasopasem is designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen, protecting normal tissue from damage associated with radiation therapy.
  • Food and Drug Administrationgranted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy.

Galera Therapeutics Announces Presentation of Avasopasem Manganese Data at ASCO 2020 Virtual Scientific Program

Retrieved on: 
Donnerstag, April 30, 2020
Physical sciences, Chemistry, Chemical substances, Radiobiology, Occupational safety and health, Radiation therapy, Radioactivity, Manganese, Hydrogen peroxide, Therapy, Superoxide dismutase mimetics

Avasopasem manganese is designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen, protecting normal tissue from damage associated with radiation therapy.

Key Points: 
  • Avasopasem manganese is designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen, protecting normal tissue from damage associated with radiation therapy.
  • No significant safety signals were observed demonstrating avasopasem manganese is well tolerated when added to a standard radiotherapy regimen.
  • Food and Drug Administrationgranted Fast Track and Breakthrough Therapy designations to avasopasem manganese for the reduction of SOM induced by radiotherapy.
  • The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem manganese for the reduction of SOM induced by radiotherapy.

Galera Therapeutics Announces Publication of GC4419 Data in the Journal of Clinical Oncology

Retrieved on: 
Donnerstag, Dezember 5, 2019
Chemical substances, Chemistry, Physical sciences, Mucositis, Antioxidants, Enzymes, Hydrogen peroxide, Superoxide dismutase mimetics

I look forward to the results of the pivotal ongoing ROMAN clinical trial which will potentially reinforce these promising findings.

Key Points: 
  • I look forward to the results of the pivotal ongoing ROMAN clinical trial which will potentially reinforce these promising findings.
  • We are pleased that our GC4419 Phase 2b data have been published in the preeminent peer-reviewed oncology journal.
  • Enrollment in our Phase 3 ROMAN clinical trial of GC4419 in patients with locally advanced head and neck cancer continues, and we anticipate reporting topline data in the first half of 2021.
  • GC4419 is designed to rapidly convert superoxide to hydrogen peroxide, reducing mucosal damage and thereby the incidence and severity of mucositis.